News and Press

ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress
June 03, 2022

ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis.

ACELYRIN, INC., Affibody AB, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
May 03, 2022

Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd., today announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50.

Bruce Cozadd joins ACELYRIN, INC. Board of Directors
March 17, 2022

Innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today announced the appointment of Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals, to its board of directors.

ACELYRIN, INC. Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
December 14, 2021

Affibody AB, and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis.